Army scientists and industry collaborators have successfully protected laboratory animals from lethal hantavirus disease using a novel approach that combines DNA vaccines and duck eggs. The work appears in a recent edition of the online scientific journal PLoS ONE, published by the Public Library of Science.
According to first author Jay W. Hooper of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), this is the first time that the DNA vaccine/duck egg system has been shown to produce an antiviral product capable of protecting against hantavirus disease.
Hantavirus causes a condition known as hantavirus pulmonary syndrome (HPS), which has a case fatality rate of 35-40 percent. Currently there are no vaccines, prophylactics, or therapeutics to prevent or treat this highly pathogenic disease.
In this study, the research team used a hamster model of Andes virus, which is the predominant cause of HPS in South America and the only hantavirus known to be transmitted person-to-person. Infection of Syrian hamsters with Andes virus, as demonstrated in earlier studies at USAMRIID, results in a disease that closely mimics human HPS in incubation time, symptoms of respiratory distress, and disease pathology. This makes it an ideal system for evaluating the feasibility of postexposure protection strategies.
Collaborating with Aldevron of Fargo, N.D. and the Universidad del Desarrollo in Santiago, Chile, Hooper and his team first evaluated a natural product, human polyclonal antibody, which was obtained as fresh frozen plasma (FFP) from a patient who survived HPS. Their results indicate that FFP shows promise as a post-exposure preventive treatment for HPS.
The team then vaccinated ducks with a DNA vaccine against Andes virus. This vaccine, initially developed and tested at USAMRIID, uses genetic material, or DNA, that encodes a specific hantavirus gene to elicit an immune response in the recip
|Contact: Caree Vander Linden|
US Army Medical Research Institute of Infectious Diseases